Roche's growth strategy is built around five interlocking priorities: advancing the next-generation oncology portfolio, expanding in neuroscience and ophthalmology, extending the diagnostics business into molecular and digital pathology, building out the personalised healthcare data infrastructure, and selectively acquiring or partnering for technologies that complement internal capabilities. In oncology, Roche's strategy has evolved from targeting well-validated biological mechanisms with single-agent therapies to developing combination regimens that address tumour heterogeneity and resistance. The bispecific antibody platform—which produces molecules that simultaneously engage two different targets, such as a cancer cell antigen and a T-cell activating receptor—is Roche's most significant oncology technology investment. Glofitamab, mosunetuzumab, and other bispecific antibodies in the pipeline represent a potential new class of oncology medicines that could rival the commercial impact of the checkpoint inhibitor wave that competitors like Bristol-Myers Squibb and Merck have dominated with Opdivo and Keytruda. Neuroscience represents Roche's most ambitious growth bet outside oncology. The success of Ocrevus in multiple sclerosis—which generated over CHF 6 billion in sales in 2023 and has become the leading MS therapy globally—validated Roche's ability to build a major neuroscience franchise. The pipeline in Alzheimer's disease, spinal muscular atrophy, and neurological rare diseases reflects a significant expansion of this ambition, though the Alzheimer's programme has faced setbacks that are discussed in the challenges section. In diagnostics, the growth strategy centres on the transition from volume-based laboratory testing toward higher-value, lower-volume molecular and genomic testing that generates more revenue per sample and carries higher margins. The digital pathology platform—which uses AI-assisted image analysis of tumour tissue slides to accelerate pathology workflow and improve diagnostic precision—is a strategic investment in the future of cancer diagnosis that positions Roche alongside the pathologist rather than being displaced by automation.